239 related articles for article (PubMed ID: 29477208)
1. Rivaroxaban in peripheral artery disease: The new kid on the block?
Hussain MA; Verma S; Al-Omran M
J Vasc Surg; 2018 Mar; 67(3):985-986. PubMed ID: 29477208
[No Abstract] [Full Text] [Related]
2. The impact of low-dose anticoagulation therapy on peripheral artery disease: insights from the VOYAGER trial.
Fukaya E; Leeper NJ
Cardiovasc Res; 2020 Oct; 116(12):e156-e158. PubMed ID: 32980875
[No Abstract] [Full Text] [Related]
3. Will COMPASS Point to a New Direction in Thrombotic Risk Reduction in Patients With Stable Cardiovascular Disease?
Boden WE; Bhatt DL
Circulation; 2018 Aug; 138(9):858-860. PubMed ID: 30354448
[No Abstract] [Full Text] [Related]
4. The evolving treatment of peripheral arterial disease: preventing ischaemic events in the post-COMPASS era.
Kaplovitch E; Anand SS
Cardiovasc Res; 2019 Oct; 115(12):e121-e124. PubMed ID: 31321405
[No Abstract] [Full Text] [Related]
5. Rivaroxaban after transcatheter aortic valve replacement: the GALILEO trial.
Giustino G; Tijssen J; Windecker S; Dangas G
Cardiovasc Res; 2020 Mar; 116(3):e39-e41. PubMed ID: 32077477
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective.
Zomer E; Si S; Hird TR; Liew D; Owen AJ; Tonkin A; Reid CM; Ademi Z
Eur J Prev Cardiol; 2019 May; 26(8):858-868. PubMed ID: 30526023
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban (Xarelto) plus aspirin for secondary prevention of cardiovascular events.
Med Lett Drugs Ther; 2018 Dec; 60(1561):196-197. PubMed ID: 30653475
[No Abstract] [Full Text] [Related]
8. A look back: the quest for thrombosis in heart failure continues after COMMANDER HF.
Filippatos G; Farmakis D
Cardiovasc Res; 2019 Nov; 115(13):e140-e142. PubMed ID: 31638158
[No Abstract] [Full Text] [Related]
9. Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease.
Liang Y; Zhu J; Liu L; Anand SS; Connolly SJ; Bosch J; Guzik TJ; O'Donnell M; Dagenais GR; Fox KA; Shestakovska O; Berkowitz SD; Muehlhofer E; Keller L; Yusuf S; Eikelboom JW;
Cardiovasc Res; 2021 Feb; 117(3):942-949. PubMed ID: 32289159
[TBL] [Abstract][Full Text] [Related]
10. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial.
Vanassche T; Verhamme P; Anand SS; Shestakovska O; Fox KA; Bhatt DL; Avezum A; Alings M; Aboyans V; Maggioni AP; Widimsky P; Berkowitz SD; Yusuf S; Connolly SJ; Eikelboom JW; Bosch J
Eur J Prev Cardiol; 2020 Feb; 27(3):296-307. PubMed ID: 31615291
[TBL] [Abstract][Full Text] [Related]
11. Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy.
Ameriso SF; Amarenco P; Pearce LA; Perera KS; Ntaios G; Lang W; Bereczki D; Uchiyama S; Kasner SE; Yoon BW; Lavados P; Firstenfeld A; Mikulik R; Povedano GP; Ferrari J; Mundl H; Berkowitz SD; Connolly SJ; Hart RG
J Stroke Cerebrovasc Dis; 2020 Aug; 29(8):104936. PubMed ID: 32689594
[TBL] [Abstract][Full Text] [Related]
12. Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease.
Ambler GK; Nordanstig J; Behrendt CA; Twine CP
Eur J Vasc Endovasc Surg; 2021 Oct; 62(4):654-655. PubMed ID: 34452837
[No Abstract] [Full Text] [Related]
13. Antithrombotic therapy in peripheral artery disease.
Foley TR; Waldo SW; Armstrong EJ
Vasc Med; 2016 Apr; 21(2):156-69. PubMed ID: 26823456
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban with or without aspirin for prevention of cardiovascular disease.
Kruger PC; Eikelboom JW; Yusuf S
Coron Artery Dis; 2018 Aug; 29(5):361-365. PubMed ID: 29346127
[No Abstract] [Full Text] [Related]
15. Rivaroxaban (Xarelto) - a new peripheral artery disease indication.
Med Lett Drugs Ther; 2021 Nov; 63(1636):172-173. PubMed ID: 35085206
[No Abstract] [Full Text] [Related]
16. The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.
Camm AJ
Thromb Haemost; 2018 May; 118(S 01):S2-S11. PubMed ID: 29566415
[TBL] [Abstract][Full Text] [Related]
17. Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context.
Patrono C
Cardiovasc Res; 2017 Dec; 113(14):e61-e63. PubMed ID: 29186439
[No Abstract] [Full Text] [Related]
18. Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Anand SS; Hiatt W; Dyal L; Bauersachs R; Berkowitz SD; Branch KRH; Debus S; Fox KAA; Liang Y; Muehlhofer E; Nehler M; Haskell LP; Patel M; Szarek M; Yusuf S; Eikelboom J; Bonaca MP
Eur J Prev Cardiol; 2022 May; 29(5):e181-e189. PubMed ID: 34463737
[TBL] [Abstract][Full Text] [Related]
19. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
[TBL] [Abstract][Full Text] [Related]
20. [The COMPASS study].
Calabrò P; Gragnano F; Visconti LO
G Ital Cardiol (Rome); 2018 Jan; 19(1):1-7. PubMed ID: 29451504
[No Abstract] [Full Text] [Related]
[Next] [New Search]
